
This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by
our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact
Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com.

https://www.wsj.com/articles/fda-set-to-get-more-power-to-pull-accelerated-drugs-that-dont-work-11654862400
A federal program that has sped hundreds of new drugs to cancer patients and others is facing the biggest makeover of its three-decade history as Congress considers ways to avoid approval of drugs that don’t work.
Congress is poised to amend the Food and Drug Administration’s accelerated-approval program to address complaints that it has sometimes led to the use of costly, ineffective drugs. Proposals in the House and Senate would give the FDA more authority to make sure companies conduct the large follow-up studies needed to confirm that a fast-tracked drug works, and to pull from the market any therapy that doesn’t.
Continue reading your article witha WSJ membership
WSJ Membership
Customer Service
Tools & Features
Ads
More
Dow Jones Products
WSJ Membership
Customer Service
Tools & Features
Ads
More
Copyright ©2022 Dow Jones & Company, Inc. All Rights Reserved

This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by
our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact
Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com.

